30% w/v) formulation of lipase inhibitor, tetrahydrolipstatin (orlistat) for oral delivery. The invention also discloses method for preparing the same under controlled temperature conditions (<40°C). The nanosized orlistat composition described in the proposed invention has effective globule size < 200 nm. The present invention discloses the novel oral concentrated nanoemulsion (up to